ABEO
Price
$6.16
Change
-$0.08 (-1.28%)
Updated
Jun 13 closing price
Capitalization
315.13M
65 days until earnings call
AUTL
Price
$2.12
Change
-$0.03 (-1.40%)
Updated
Jun 13 closing price
Capitalization
564.21M
47 days until earnings call
Interact to see
Advertisement

ABEO vs AUTL

Header iconABEO vs AUTL Comparison
Open Charts ABEO vs AUTLBanner chart's image
Abeona Therapeutics
Price$6.16
Change-$0.08 (-1.28%)
Volume$373.89K
Capitalization315.13M
Autolus Therapeutics
Price$2.12
Change-$0.03 (-1.40%)
Volume$1.9M
Capitalization564.21M
ABEO vs AUTL Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. AUTL commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and AUTL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (ABEO: $6.16 vs. AUTL: $2.12)
Brand notoriety: ABEO and AUTL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 18% vs. AUTL: 78%
Market capitalization -- ABEO: $315.13M vs. AUTL: $564.21M
ABEO [@Biotechnology] is valued at $315.13M. AUTL’s [@Biotechnology] market capitalization is $564.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileAUTL’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • AUTL’s FA Score: 0 green, 5 red.
According to our system of comparison, AUTL is a better buy in the long-term than ABEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 3 TA indicator(s) are bullish while AUTL’s TA Score has 6 bullish TA indicator(s).

  • ABEO’s TA Score: 3 bullish, 4 bearish.
  • AUTL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -8.61% price change this week, while AUTL (@Biotechnology) price change was -9.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

AUTL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($564M) has a higher market cap than ABEO($315M). ABEO YTD gains are higher at: 10.592 vs. AUTL (-9.787). ABEO has higher annual earnings (EBITDA): -64.95M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. ABEO (110M). ABEO has less debt than AUTL: ABEO (23.1M) vs AUTL (57.7M). AUTL has higher revenues than ABEO: AUTL (9.01M) vs ABEO (0).
ABEOAUTLABEO / AUTL
Capitalization315M564M56%
EBITDA-64.95M-226.02M29%
Gain YTD10.592-9.787-108%
P/E RatioN/AN/A-
Revenue09.01M-
Total Cash110M517M21%
Total Debt23.1M57.7M40%
FUNDAMENTALS RATINGS
ABEO vs AUTL: Fundamental Ratings
ABEO
AUTL
OUTLOOK RATING
1..100
2224
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4339
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (39) in the Biotechnology industry is in the same range as ABEO (61) in the Pharmaceuticals Generic industry. This means that AUTL’s stock grew similarly to ABEO’s over the last 12 months.

AUTL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that AUTL’s stock grew similarly to ABEO’s over the last 12 months.

AUTL's SMR Rating (94) in the Biotechnology industry is in the same range as ABEO (97) in the Pharmaceuticals Generic industry. This means that AUTL’s stock grew similarly to ABEO’s over the last 12 months.

AUTL's Price Growth Rating (39) in the Biotechnology industry is in the same range as ABEO (43) in the Pharmaceuticals Generic industry. This means that AUTL’s stock grew similarly to ABEO’s over the last 12 months.

AUTL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that AUTL’s stock grew similarly to ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOAUTL
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIFGX12.29N/A
N/A
MFS Diversified Income R4
RYCVX164.55N/A
N/A
Rydex Dow 2x Strategy H
SOPYX32.26N/A
N/A
ClearBridge Dividend Strategy I
SCSAX16.68N/A
N/A
Allspring Common Stock A
MXMSX10.54N/A
N/A
Empower Small Cap Growth Instl

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ERAS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
-1.36%
ERAS - ABEO
47%
Loosely correlated
-3.27%
ZYME - ABEO
45%
Loosely correlated
-3.28%
CRNX - ABEO
45%
Loosely correlated
-1.24%
APGE - ABEO
45%
Loosely correlated
+6.26%
DAWN - ABEO
44%
Loosely correlated
-0.30%
More

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-1.40%
CRSP - AUTL
47%
Loosely correlated
+0.19%
ERAS - AUTL
44%
Loosely correlated
-3.27%
IMCR - AUTL
44%
Loosely correlated
-2.67%
OCUL - AUTL
44%
Loosely correlated
-2.46%
ABEO - AUTL
43%
Loosely correlated
-1.36%
More